BD this week announced that it has received FDA 510(k) clearance for expanded indications for its Rotarex atherectomy system.
Franklin Lakes, N.J.-based BD designed the Rotarex as a rotational excision device that removes and aspirates varying lesion morphologies in the peripheral arteries.
Get the full story on our sister site, Medical Tubing + Extrusion.
BD (NYSE:BDX) announced today that it increased its manufacturing capacity and domestic supply for syringes and needles.
Franklin Lakes, N.J.-based BD’s new syringe and needle manufacturing lines, which were completed on an accelerated timeline, represent BD’s partnership with Department of Health and Human Services’ (HHS) Assistant Secretary for Preparedness and Response (ASPR).
Get the full story at our sister site, Drug Delivery Business News.
AdvaMed this week honored former BD CEO Edward Ludwig with its 2021 AdvaMed Lifetime Achievement Award.
Ludwig received the award on September 27 during an in-person and live-streamed event as part of The MedTech Conference.
Ludwig joined BD in 1979 and rose through the ranks to eventually become chair and CEO, retiring from the company in 2012.
AdvaMed in a news release praised the leadership that Ludwig demonstrated at BD:
He was instrumental in bringing the BD BACTEC 9000 system to market, a family of continuous blood monitoring and blood culturing instruments, revolutionizing the way blood culturing was performed, ultimately improving patient care and safety for health care workers.
With the goal of developing current and future leaders in the company, Ludwig established BD University, a management-driven leadership development program within the company. At BD, everyone who worked with him could tell you abo…
BD (NYSE:BDX) today shared the results from a preliminary study investigating the impact of deep cold storage on glass prefillable syringes.
Franklin Lakes, N.J.-based BD’s study evaluated deep cold storage (-20°C and -40°C) as traditional vaccine formulations are commonly stored up to about 2°C to 8°C, while mRNA vaccine formulations (the type of COVID-19 vaccine made by both Pfizer and Moderna), among other new ones, require much colder storage for over a long period of time to ensure drug-product shelf-life and potency.
Get the full story at our sister site, Drug Delivery Business News.
After several weeks of high-level performance, the medtech industry saw its first dip in a while over the last seven days.
MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (Aug. 13) at 117.92 points, marking a -1.2% dip from the 119.41-point tally a week prior (Aug. 6).
Medtech’s performance continues to reflect an overall rebound from the struggles brought on by the COVID-19 pandemic, too. The industry remains well above the marks set around the height of the pandemic, having registered a 27.7% increase from the pre-pandemic high of 92.32 (set on Feb. 19, 2020). Moreover, it remains well ahead of the mid-pandemic low of 62.13 (March 23, 2020) as well, totaling an 89.8% ascent above that point.
The industry’s performance did not correlate with the overall markets this past week as the S&P 500 Index and Dow Jones Industrial Average fared almost identically, ticking up by 0.7% a…
Flow cytometry is a powerful technology given its ability to analyze the physical and chemical properties of cells and particles.
But many laboratories struggle to find space for advanced flow cytometry cell analyzers.
BD (NYSE:BDX) has responded to that challenge with its benchtop FACSymphony A1 cell analyzer.
BD designed the fluorescence-activated cell analyzer to support modern research demands in a small footprint.
The analyzer can precisely isolate single cells from complex samples. It supports small particle research as well as 16-color immunophenotyping.
The FACSymphony A1 “offers high-end technology and a cost-effective benchtop design,” surmised Thomas E. Polen, BD CEO, in a recent earnings calls.
The FACSymphony A1 cell analyzer supports various types of flow cytometry experiments. In addition, an optional small particle detector enables the analysis of extracellular vesicles.
BD recently debuted its spectral analyze…
BD (NYSE: BDX) today said it has appointed Christopher DelOrefice as executive VP and chief financial officer, effective Sept. 6.
DelOrefice currently serves as the VP of investor relations at Johnson & Johnson and has held numerous leadership roles within the company for more than 20 years. Prior to joining J&J, DelOrefice held leadership positions at AstraZeneca Pharmaceuticals, AET Films and Ametek.
“Chris has the right mix of strong operational and corporate finance experience that is highly relevant to his new role as CFO at BD,” president and CEO Tom Polen said in a news release. “His deep experience in health care and medical technology — including supporting multiple large businesses and functions at J&J — will help create a seamless transition as CFO. His investor relations expertise provides additional value to the investment community who know him well. Chris’s track record leading and developing strong finance teams will be an asset to B…
The medtech industry has been rising for weeks and the latest seven-day stretch was no exception as stocks ticked up again.
MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (Aug. 6) at 119.41 points, marking a 0.5% rise from the previous week’s tally of 118.86 points (July 30). Not including the the week in which the index shot up to 145.88 points and quickly tumbled down, the latest marks would represent the index’s all-time best.
Medtech’s performance continues to reflect an overall rebound from the struggles brought on by the COVID-19 pandemic, too. The industry has registered a 29.3% increase from the pre-pandemic high of 92.32 (set on Feb. 19, 2020). Moreover, it remains well ahead of the mid-pandemic low of 62.13 (March 23, 2020) as well, totaling a 92.2% ascent above that point.
The industry’s performance did not correlate with the overall markets this past week as t…
BD (NYSE: BDX) posted second-quarter results today that beat the consensus forecast on Wall Street, increasing its full-year guidance.
The medtech giant, however, also acknowledged that it’s seeing the COVID-19 delta variant impact elective procedure volumes in some U.S. states.
Franklin Lakes, N.J.–based BD reported profits of $525 million, or $1.72 per share, on sales of $4.89 billion for the three months ended June 30, 2021, for a bottom-line gain of 81.2 % and sales growth of 26.9% compared with Q2 2020.
Adjusted to exclude one-time items, earnings per share were $2.74, 30¢ ahead of The Street, where analysts were looking EPS of $2.44 on sales of $4.51 billion.
“Our strong third-quarter results reflect continued momentum across our base business,” BD CEO Tom Polen said in a news release. “Solid execution by our teams has strengthened our foundation, while increased investment in R&D and tuck-in M&A are enhancing our innovation pi…
The medtech industry remains on the upswing as companies see their stocks rising with quarterly earnings providing a boost.
MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (July 30) at 118.86 points. Two weeks ago aside — when the index shot up to 145.88 points and quickly tumbled down — this mark would be the index’s all-time best.
The total at the end of last week represents a 2.9% rise from the 115.54-point tally posted by the index at the end of last week (July 23).
Medtech’s performance continues to reflect an overall rebound from the struggles brought on by the COVID-19 pandemic, too. The industry has registered a 28.7% increase from the pre-pandemic high of 92.32 (set on Feb. 19, 2020). Moreover, it remains well ahead of the mid-pandemic low of 62.13 (March 23, 2020) as well, totaling a 91.3% ascent above that point.
The industry’s performance had no cor…
BD (NYSE:BDX) announced today that it will begin remediation for a 2020 recall of its Alaris infusion system.
Franklin Lakes, N.J.-based BD’s remediation for the Feb. 4, 2020, recall of the BD Alaris system will begin through a new version of software after a voluntary recall alerted customers to a number of areas in which the pump may not operate as expected. Those areas included software errors related to System Error Code 255-XX-XXX, delay options programming, low battery alarm failure, keep vein open/End of Infusion alarms priority and user errors related to Customer Concentrations Programming.
Get the full story at our sister site, Drug Delivery Business News.
BD (NYSE:BDX) today announced that it has acquired resorbable polymer technology maker Tepha for an undisclosed amount.
Franklin Lakes, N.J.–based BD said that it will use Lexington, Mass.–based Tepha’s resorbable polymer technology to accelerate growth of the company’s surgical mesh for soft tissue repair, reconstruction and regeneration. Tepha’s GalaFlex portfolio is also included in the acquisition.
“This strategic acquisition advances BD’s category leadership in surgical mesh and enables future innovations to provide new solutions to physicians and their patients,” Kevin Kelly, worldwide president for BD Surgery, said in a news release.
Get the full story on our sister site MassDevice.